In the article, “Elon Musk’s Neuralink wins FDA approval for human study of brain implants,” Reuters examined the FDA’s decision to clear Neuralink for its first-in-human clinical trials despite ongoing investigations surrounding its handling of animal experiments. They interviewed Dr. Victor Krauthamer, a visiting biomedical engineering professor at GW, for his expertise on the matter as he spent three decades working at the FDA.
Here is an excerpt from the article: “If the animal testing is unreliable, then (human trial) approval may be based on flawed animal safety data. The FDA should have verified their trust of animal study results,” Krauthamer said.
Read the full article on Reuters. For another article on this topic featuring Dr. Krauthamer, visit the Guardian.